Dr Rosemary Balleine

Translational Oncology

• Research Interests
• Publications
• Contact Details

Rosemary Balleine is a medical graduate of the University of Sydney who trained as a Pathologist at Westmead Hospital, obtaining Fellowship of the Royal College of Pathologists of Australasia in 1999.

In the course of her medical training she obtained a PhD from the University of Sydney for studies on breast cancer under the supervision of Associate Professor Christine Clarke and Professor Rick Kefford of the Westmead Institute for Cancer Research.

She is currently a Cancer Institute NSW Fellow and research group leader in Translational Oncology.

Research Interests

Translational Oncology is concerned with the exchange of ideas and information between the cancer research laboratory and the oncology clinic. As a group leader in Translational Oncology, Dr Balleine is involved in a range of clinically orientated research projects.

She has continued her interest in the investigation of breast cancer and on-going projects in the lab include investigations into the nature of early breast cancer and the pathology of familial breast cancer.

Publications

- 2007 - 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 -

2007

• Gurney, H, Wong, M, Balleine, RL, Rivory, LP, McLachlan, AJ, Hoskins, JM, Wilcken, N, Clarke, CL, Mann,GJ, Collins, M, Delforce, SE, Lynch, K, Schran, H. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 2007 Jul;82(1):33-40 [Abstract]

2006

• Balleine, R, Murali, R, Bilous, A, Farshid, G, Waring, P, Provan, P, Byth, K, Thorne, H, , K, Kirk, J. Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology. 2006; 49:523-32 [Abstract]
• Farshid, G, Balleine, R, Cummings, M, Waring, P, , T. Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing. The American Journal of Surgical Pathology. 2006; 30:1357-1366 [Abstract]
• Wong, M, Balleine, R, Blair, E, McLachlan, A, Ackland, S, Garg, M, Evans, S, Farlow, D, Collins, M, Rivory, L, Hoskins, J, Mann, G, Clarke, C, Gurney, H. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24:2448-55 [Abstract]
• Guminski, A, Balleine, R, Chiew, Y, Webster, L, Tapner, M, Farrell, G, Harnett, P, Defazio, A. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology. 2006; 100:239-46 [Abstract]
• Mann, G, Thorne, H, Balleine, R, Butow, P, Clarke, C, Edkins, E, Evans, G, Fereday, S, Haan, E, Gattas, M, Giles, G, Goldblatt, J, Hopper, J, Kirk, J, Leary, J, Lindeman, G, Niedermayr, E, Phillips, K, Picken, S, Pupo, G, Saunders, C, Scott, C, Spurdle, A, Suthers, G, Tucker, K, Chenevix-Trench, G, , K. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research : BCR. 2006; 8:R12 [Abstract]

2005

• Byrne, J, Balleine, R, Fejzo, M, Mercieca, J, Chiew, Y, Livnat, Y, St Heaps, L, Peters, G, Byth, K, Karlan, B, Slamon, D, Harnett, P, Defazio, A. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer. Journal International du Cancer. 2005; 117:1049-54 [Abstract]
• Webster, L, Bilous, A, Willis, L, Byth, K, Burgemeister, F, Salisbury, E, Clarke, C, Balleine, R. Histopathologic indicators of breast cancer biology: insights from population mammographic screening. British Journal of Cancer. 2005; 92:1366-71 [Abstract]
• Wong, M, Evans, S, Rivory, L, Hoskins, J, Mann, G, Farlow, D, Clarke, C, Balleine, R, Gurney, H. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology and Therapeutics. 2005; 77:33-42 [Abstract]

2004

• Wong, M, Balleine, R, Collins, M, Liddle, C, Clarke, C, Gurney, H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clinical Pharmacology and Therapeutics. 2004; 75:529-38 [Abstract]
• Balleine, R, Earls, P, Webster, L, Mote, P, deFazio, A, Harnett, P, Clarke, C. Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 2004; 23:138-44 [Abstract]

2002

• Balleine, R, Kefford, R. Targeting molecular mechanisms in cancer. ANZ Journal Of Surgery. 2002; 72:760-763

2001

• Balleine, R, Humphrey, K, Clarke, C. Tumour banks: providing human tissue for cancer research. Medical Journal of Australia. 2001; 41:320-325

2000

• Mote, P, Balleine, R, Mcgowan, E, Clarke, C. Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Human Reproduction. 2000; 15:48-56
• Balleine, R, Schoenberg Fejzo, M, Sathasivam, P, Basset, P, Clarke, C, Byrne, J. The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes, Chromosomes & Cancer. 2000; 29:48-57

Contact Details

T +61 2 9845 8086
F +61 2 9845 9102
E rosemary_balleine@wmi.usyd.edu.au